Top

Published in:

01-09-2012 | Short Communication

Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition

Authors: Milena Perez Mak, Verônica Torres da Costa e Silva, Regina Matsunaga Martin, Antonio Marcondes Lerario, Luis Yu, Paulo Marcelo Gehm Hoff, Gilberto de Castro Junior

Published in: Supportive Care in Cancer | Issue 9/2012

Abstract

Purpose

Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures.

Method

Case report.

Result

We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO.

Conclusion

This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.

Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef

Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Canc 18:R53–R77CrossRef

Cotant CL, Rao PS (2007) Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. Am J Kidney Dis 50:1033–1036PubMedCrossRef

Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef

Wilkins GE, Granleese S, Hegele RG, Holden J, Anderson DW, Bondy GP (1995) Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 80:1628–1634PubMedCrossRef

Pelger RC, Lycklama ANGA, Papapoulos SE, Hamdy NA (2005) Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone 36:1–5PubMedCrossRef

Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL (2005) Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol 23:3626–3628PubMedCrossRef

Hosking DJ, Chamberlain MJ, Shortland-Webb WR (1975) Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium. Br J Radiol 48:451–456PubMedCrossRef

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822PubMedCrossRef

10.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Canc Inst 96:879–882CrossRef

Title: Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition
Authors: Milena Perez Mak
Verônica Torres da Costa e Silva
Regina Matsunaga Martin
Antonio Marcondes Lerario
Luis Yu
Paulo Marcelo Gehm Hoff
Gilberto de Castro Junior
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1474-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2012

A dietitian-led clinic for patients receiving (chemo)radiotherapy for head and neck cancer

Patients' goals related to health and function in the first 13 months after allogeneic stem cell transplantation

Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism

A new palliative care consultation team at the oncology department of a university hospital: an assessment of initial efficiency and effectiveness

Demonstration and manifestation of self-determination and illness resistance—A qualitative study of long-term maintenance of physical activity in posttreatment cancer survivors

The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer